FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094138148> ?p ?o ?g. }

• W2094138148 abstract "Breast cancer is the most commonly diagnosed form of cancer in women. Among breast cancer patients about 2/3 are initially hormone sensitive or estrogen receptor (ER) positive and respond to endocrine therapy. Aromatase inhibitors (AI9s) are superior class of hormonal therapeutic agents effectively control ER positive breast cancer in postmenopausal women. Acquired resistance to AI9s is expected to be an emerging serious problem in clinics and recent studies have shown that tumors use adaptive signaling mechanisms to overcome AI sensitivity. Thus there is an urgent need for newer treatment modalities. Combination of endocrine and non endocrine agents that block these signaling pathways may prevent or delay the adaptive mechanism and thereby onset of resistance to hormonal therapy. In our study we have found that Fidarestat, an aldose reductase (enzyme which catalyzes the rate limiting step of glucose to fructose or sorbitol formation in polyol pathway) inhibitor effectively re-sensitize letrozole resistant LTLT-Ca breast cancer cells to letrozole. 1µM of fidarestat + 1uM letrozole was found very effective in inducing maximum cell death in LTLT-Ca cells when compared to fidarestat alone. The combination treatment not only restored ER-α levels but also down regulated HER2/MAPK signaling proteins. Aldose reductase siRNA (100nM)- treated MCF-7/Aro and MCF-7 cells upregulated ER-α in western blot and ER-functionality assays. On the other hand in aldose reductase-siRNA- treated LTLT-Ca cells, ER-α levels were down- regulated as in fidarestat treatment. Pretreatment of LTLT-Ca with fidarestat for one week showed reduced proliferation of cells and the effect was maintained until four passages with 1µM letrozole alone. Fidarestat treatment up-regulated E2-mediated transcription in LTLT-Ca cells. In order to enhance the efficacy and targeted delivery of fidarestat in LTLT–Ca cells we have used a nanoparticle-based therapeutic formulation. Folate receptor, highly expressed on epithelial carcinomas, could be a potential molecular target for tumor selective drug delivery. Physcio-chemically well characterized Fidarestat–folate nanoparticles (FFNP9s) were prepared to increase the tumor selective intracellular delivery. FFNP9s were found superior in exerting cytotoxicity when compared to fidarestat alone. Combination therapy was equally effective in controlling LTLT-Ca cell growth using xenograft model. Taken together, the increased glucose metabolism in LTLT-Ca cells may be critically contributing to chemotherapeutic resistance by increasing drug metabolism and decreasing uptake. Hence targeting aldose reductase in endocrine resistance may be attractive alternative to increase the sensitivity of hormonal therapy. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 67." @default.
• W2094138148 created "2016-06-24" @default.
• W2094138148 creator A5009312646 @default.
• W2094138148 creator A5010406195 @default.
• W2094138148 creator A5010621060 @default.
• W2094138148 creator A5012007927 @default.
• W2094138148 creator A5031605337 @default.
• W2094138148 creator A5054763940 @default.
• W2094138148 creator A5073379936 @default.
• W2094138148 date "2009-12-15" @default.
• W2094138148 modified "2023-09-27" @default.
• W2094138148 title "Targeting Aldose Reductase: A Novel Strategy in Treating Endocrine Resistance Using Combination Therapy." @default.
• W2094138148 doi "https://doi.org/10.1158/0008-5472.sabcs-09-67" @default.
• W2094138148 hasPublicationYear "2009" @default.
• W2094138148 type Work @default.
• W2094138148 sameAs 2094138148 @default.
• W2094138148 citedByCount "1" @default.
• W2094138148 countsByYear W20941381482015 @default.
• W2094138148 crossrefType "proceedings-article" @default.
• W2094138148 hasAuthorship W2094138148A5009312646 @default.
• W2094138148 hasAuthorship W2094138148A5010406195 @default.
• W2094138148 hasAuthorship W2094138148A5010621060 @default.
• W2094138148 hasAuthorship W2094138148A5012007927 @default.
• W2094138148 hasAuthorship W2094138148A5031605337 @default.
• W2094138148 hasAuthorship W2094138148A5054763940 @default.
• W2094138148 hasAuthorship W2094138148A5073379936 @default.
• W2094138148 hasConcept C121608353 @default.
• W2094138148 hasConcept C126322002 @default.
• W2094138148 hasConcept C134018914 @default.
• W2094138148 hasConcept C185592680 @default.
• W2094138148 hasConcept C2776166826 @default.
• W2094138148 hasConcept C2776439734 @default.
• W2094138148 hasConcept C2778812593 @default.
• W2094138148 hasConcept C502942594 @default.
• W2094138148 hasConcept C530470458 @default.
• W2094138148 hasConcept C555293320 @default.
• W2094138148 hasConcept C71924100 @default.
• W2094138148 hasConcept C84606932 @default.
• W2094138148 hasConcept C98274493 @default.
• W2094138148 hasConceptScore W2094138148C121608353 @default.
• W2094138148 hasConceptScore W2094138148C126322002 @default.
• W2094138148 hasConceptScore W2094138148C134018914 @default.
• W2094138148 hasConceptScore W2094138148C185592680 @default.
• W2094138148 hasConceptScore W2094138148C2776166826 @default.
• W2094138148 hasConceptScore W2094138148C2776439734 @default.
• W2094138148 hasConceptScore W2094138148C2778812593 @default.
• W2094138148 hasConceptScore W2094138148C502942594 @default.
• W2094138148 hasConceptScore W2094138148C530470458 @default.
• W2094138148 hasConceptScore W2094138148C555293320 @default.
• W2094138148 hasConceptScore W2094138148C71924100 @default.
• W2094138148 hasConceptScore W2094138148C84606932 @default.
• W2094138148 hasConceptScore W2094138148C98274493 @default.
• W2094138148 hasLocation W20941381481 @default.
• W2094138148 hasOpenAccess W2094138148 @default.
• W2094138148 hasPrimaryLocation W20941381481 @default.
• W2094138148 hasRelatedWork W1487727696 @default.
• W2094138148 hasRelatedWork W1561012079 @default.
• W2094138148 hasRelatedWork W1978152553 @default.
• W2094138148 hasRelatedWork W2026151244 @default.
• W2094138148 hasRelatedWork W2028757191 @default.
• W2094138148 hasRelatedWork W2058677742 @default.
• W2094138148 hasRelatedWork W2060286288 @default.
• W2094138148 hasRelatedWork W2091273073 @default.
• W2094138148 hasRelatedWork W2335291668 @default.
• W2094138148 hasRelatedWork W2356195641 @default.
• W2094138148 hasRelatedWork W2464064339 @default.
• W2094138148 hasRelatedWork W2486750055 @default.
• W2094138148 hasRelatedWork W2593948541 @default.
• W2094138148 hasRelatedWork W2784726529 @default.
• W2094138148 hasRelatedWork W2808838194 @default.
• W2094138148 hasRelatedWork W2887987406 @default.
• W2094138148 hasRelatedWork W2944710608 @default.
• W2094138148 hasRelatedWork W2951148599 @default.
• W2094138148 hasRelatedWork W3017143012 @default.
• W2094138148 hasRelatedWork W3034336089 @default.
• W2094138148 isParatext "false" @default.
• W2094138148 isRetracted "false" @default.
• W2094138148 magId "2094138148" @default.
• W2094138148 workType "article" @default.